Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Sean E McGuire Image

      Sean E McGuire, MD, PhD

      Department of GU Radiation Oncology, Division of Radiation Oncology

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX

      Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Associate Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX

      Associate Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2004Baylor College of Medicine, Houston, Texas, US, MD
      2003Baylor College of Medicine, Houston, Texas, US, Ph.D. in Molecular & Cellular Biology
      1994Harvard University, Cambridge, Massachusetts, US, BA in Biochemistry

      Postgraduate Training

      2005-2009Clinical Residency, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2004-2005Clinical Internship, Internal Medicine, The University of Texas Health Science at Houston, Houston, Texas

      Licenses & Certifications

      2011DEA Registration
      2009Texas Medical License
      2009American Board of Radiology
      nullBasic Life Support
      nullFlorida Board of Medicine

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX, 2009 - 2019

      Assistant Professor, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2016

      Other Professional Positions

      Member, Department of Molecular & Cellular Biology Standing Examination Committee of the Graduate Program, Baylor College of Medicine, Houston, TX, 2011 - 2014

      Member, MD/PhD Faculty Operating Committee, Baylor College of Medicine, Houston, TX, 2011 - 2012

      Extramural Institutional Committee Activities

      Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020 - 2023

      Honors & Awards

      2019MD Anderson Top Performer, Top 1% Nationally in Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) Survey, The University of Texas MD Anderson Cancer Center
      2018Distinguished Alumnus Award, Baylor College of Medicine
      2015Prostate Cancer Foundation Young Investigator Award
      2012UT MD Anderson Physician Scientist Program
      2010Distinguished Young Alumnus Award, Baylor College of Medicine
      2004Donald B. Lindsey Prize, Society for Neuroscience
      2004Larry Sandler Award, Genetics Society of America for Outstanding Ph.D., thesis
      2003Harold Weintraub Award, Fred Hutchinson Cancer Center
      1998John J. Trentin Award for Scholastic Excellence, Baylor College of Medicine
      1997Anthony R. Means Award for Scholastic Excellence, Baylor College of Medicine
      1994B.A. with Honors Biochemistry, Harvard University
      1993Ford Grant for Undergraduate Research in Laboratory of Mark Ptashne, Harvard University
      1990National Merit Finalist and Scholarship Recipient
      1990Selection to American Delegation to the Wiezman Institutes Summer Science Program
      1990Westinghouse National Science Talent Search Finalist
      1990Milken Foundation Award and Invitation to American Academy of Achievement Conference
      1989Stanford Book Prize

      Professional Memberships

      American Society of Clinical Oncology

      2012 - Present

      American Association for Cancer Research

      2011 - Present

      American Society for Radiation Oncology

      2011 - Present

      Radiological Society of North America

      2006 - Present

      Selected Presentations & Talks

      Local Presentations

      1. 2002. The role of Drosophila mushroom body signaling in olfactory memory. Conference. The role of Drosophila mushroom body signaling in olfactory memory. Houston, TX, US.
      2. 2002. Understanding the function of genes and neurons involved in learning and memory in Drosophila. Conference. Understanding the function of genes and neurons involved in learning and memory in Drosophila. Houston, TX, US.
      3. 2002. The role of Drosophila mushroom body signaling in olfactory memory. Conference. The role of Drosophila mushroom body signaling in olfactory memory. Houston, TX, US.

      Regional Presentations

      1. 2003. Temporal and spatial rescue of the rutabaga memory defect. Conference. Temporal and spatial rescue of the rutabaga memory defect, US.
      2. 1998. Poster presentation, Chromosomal assignments of human 27 kDa heat shock protein. Conference. Poster presentation, Chromosomal assignments of human 27 kDa heat shock protein. San Antonio, TX, US.
      3. 1993. IGF-Binding proteins correlate with clinical parameters in breast cancer. Conference. IGF-Binding proteins correlate with clinical parameters in breast cancer. San Antonio, TX, US.
      4. 1990. The sensitive detection of HER-2 oncogene expression in breast cancer by polymerase chain reaction. Conference. The sensitive detection of HER-2 oncogene expression in breast cancer by polymerase chain reaction. San Antonio, TX, US.

      National Presentations

      1. 2011. American Association for Cancer Research. Conference. American Association for Cancer Research. San Francisco, CA, US.
      2. 2011. Prostate Cancer Foundation Eighteenth Annual Scientific Retreat. Conference. Prostate Cancer Foundation Eighteenth Annual Scientific Retreat. Lake Taho, NV, US.
      3. 2011. ASCO/AACR Methods in Clinical Cancer Research. Conference. ASCO/AACR Methods in Clinical Cancer Research. Vail, CO, US.
      4. 2011. Changing Landscape of the Cancer Genome (F3). Conference. Bayer USA Foundation, Novartis Institutes for Biomedical Research, Onyx Pharmaceuticals, Inc. and Pfizer Inc. Boston, MA, US.
      5. 2011. Paired-end sequencing identifies recurrently rearranged genes in prostate cancer. Conference. The Changing landscape of the Cancer Genome. Boston, MA, US.
      6. 2011. Paired-end sequencing identifies recurrently rearranged genes in prostate cancer. Conference. The Cancer Genome Atlas Symposium,. Durham, NC, US.
      7. 2011. RTOG - Semi Annual Meeting. Conference. RTOG - Semi Annual Meeting. San Diego, CA, US.
      8. 2010. Androgen Receptor Signaling in Prostate Cancer: Translating Biology into Clinical Practice. Conference. Androgen Receptor Signaling in Prostate Cancer: Translating Biology into Clinical Practice. Arlington, VA, US.
      9. 2010. PSA Response to Neoadjuvant Androgen Ablation Prior to Radiotherapy Predicts Outcome in Clinically localized High Risk Prostate Cancer. Conference. PSA Response to Neoadjuvant Androgen Ablation Prior to Radiotherapy Predicts Outcome in Clinically localized High Risk Prostate Cancer. San Diego, CA, US.
      10. 2005. Radiation is an important component of treatment for Stage III breast cancer patients after a pathologic complete response to neoadjuvant chemotherapy. Conference. Radiation is an important component of treatment for Stage III breast cancer patients after a pathologic complete response to neoadjuvant chemotherapy. Denver, CO, US.
      11. 2005. The Larry Sandler Memorial Award Lecture. Conference. The Larry Sandler Memorial Award Lecture. Washington, DC, US.
      12. 2003. Temporal and regional gene expression targeting with the conventional GAL4/UAS system in drosophila. Conference. Temporal and regional gene expression targeting with the conventional GAL4/UAS system in drosophila. Chicago, IL, US.
      13. 2003. Temporal and spatial rescue of the rutabaga memory defect. Conference. Temporal and spatial rescue of the rutabaga memory defect. Cold Spring, NY, US.
      14. 2002. The role of drosophila mushroom body signaling in olfactory memory. Conference. The role of drosophila mushroom body signaling in olfactory memory. Snowmass, CO, US.
      15. 2001. The temporal requirements for mushroom body signaling during memory acquisition, storage and retrieval. Conference. The temporal requirements for mushroom body signaling during memory acquisition, storage and retrieval. San Diego, CA, US.
      16. 2001. The role of drosophila mushroom body signaling in olfactory memory. Conference. The role of drosophila mushroom body signaling in olfactory memory. Cold Springs Harbor, NY, US.
      17. 1990. The use of the polymerase chain reaction to measure HER-2 oncogene expression in breast tumor biopsies. Conference. The use of the polymerase chain reaction to measure HER-2 oncogene expression in breast tumor biopsies. Washington, DC, US.

      International Presentations

      1. 2011. ESTRO Anniversary Congress. Conference. ESTRO Anniversary Congress. London, GB.

      Formal Peers

      1. 2014. Identification of a Pan-cancer Oncogenic microRNA 'Superfamily' Anchored by a Central Core Seed Motif. Invited. Houston, TX, US.
      2. 2011. Workshop on Ethical Approaches to Genotype-Driven Research Recruitment. Invited. Durham, NC, US.
      3. 2005. Presentation of the Larry Sandler Memorial Lecture. Visiting. Washington, DC, US.
      4. 1995. Adenoviral Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase (HSV-tk) in an Ascites Model of Human Breast Cancer. Invited, TX, US.
      5. 1990. Synthesis and characterization of non-specific tumor-associated antigen crosslinks. Invited. Rehovot, IL.
      Read More
      Less

      Grant & Contract Support

      Date: 2018 - 2022
      Title:5W81XWH18-0299 Enhancing Outcomes of Radiation Therapy for Prostate Cancer
      Funding Source:Department of Defense (DOD)
      Role:PI
      ID:PC170807P1
      Date: 2016 - 2021
      Title:Center for Reproductive Biological Research
      Funding Source:NIH/NICHD
      Role:Co-I
      Date: 2016 - 2021
      Title:Identification of Placental miRNA Targets and Integrated ‘Omics
      Funding Source:NIH/NICHD
      Role:Co-I
      ID:R01 HD089655
      Date: 2016 - 2019
      Title:5R21CA205257-02 The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
      Funding Source:NIH/NCI
      Role:PI
      ID:1 R21 CA205257-01
      Date: 2015 - 2018
      Title:Young Investigator Award
      Funding Source:Prostate Cancer Foundation
      Role:PI
      ID:PCF 2015 YI768
      Date: 2013 - 2017
      Title:The Landscape of Genomic Rearrangements in Prostate Cancer as Drivers of Altered Cellular Energy Metabolism – An Integrative Genomic and Metabolomics Screen for Novel Therapeutic Targets
      Funding Source:Diana Helis Henry Medical Research Foundation
      Role:PI
      Date: 2012 - 2017
      Title:UT MD Anderson Cancer Center Physician Scientist Program
      Funding Source:MD Anderson
      Role:PI
      Date: 2012 - 2015
      Title:Honorable A. David Mazzone Special Challenge Award
      Funding Source:Prostate Cancer Foundation
      Role:Co-I
      Date: 2010 - 2011
      Title:Genome-Wide Mapping of Structural Rearrangements in Prostate Cancer
      Funding Source:Dan L. Duncan Cancer Center Pilot Grant
      Role:PI
      Title:Ethel A and Raymond Willeke Fund
      Funding Source:Ethel A and Raymond Willeke Fund
      Role:PI
      Title:Caroline Wiess Law Scholar Award Fund
      Funding Source:Caroline Wiess Law Foundation
      Role:PI

      Selected Publications

      Peer-Reviewed Articles

      1. El Kouzi, Z, Mohammed, MA, Rooney, M, Kouzy, R, Chen, JJ, Shah, SJ, Al Bitar, T, Gadoue, S, Hassanzadeh, CJ, Frank, SJ, Tran, P, Tang, C, Choi, S, Park, RJ, Hoffman, K, McGuire, SE, Mok, H, Nguyen, Q, Samman, AB, Rahman, Z, Shelan, M, Eid, T, Mohamad, O. Association between author specialty and reported outcomes in non-randomized comparisons of prostatectomy versus radiation. JNCI Cancer Spectrum 10(4), 2026. e-Pub 2026. PMID: 42390011.
      2. Chapin, BF, Smaldone, MC, Zurita-Saavedra, A, Wang, RJ, Cooperberg, MR, Gleave, ME, Delacroix, SE, Davis, JW, Pettaway, CA, Pisters, LL, Adibi, M, Chery, LJ, Papadopoulos, JN, Ward, JF, Gregg, JR, Navai, N, Corn, P, Subudhi, SK, Logothetis, CJ, Kuban, DA, Nguyen, Q, Tang, C, Choi, S, Hoffman, K, Lozano, M, Elsheftawi, M, Achim, M, Zhao, Y, Ramesh, N, Sei, E, Navin, N, Nogueras Gonzalez, G, Wang, X, Zhu, K, Troncoso, P, Zhang, M, McGuire, SE, Aparicio, A. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European urology 90(2):125-136, 2026. e-Pub 2026. PMID: 41833492.
      3. Hassanzadeh, CJ, Kuban, DA, Pasyar, S, Bassett Jr, R, Troncoso, P, Ansari, M, Schlembach, PJ, McGuire, SE, Nguyen, Q, Frank, SJ, Mok, H, Mohamad, O, Park, RJ, Tang, C, Du, W, Kudchadker, RJ, Choi, S, Hoffman, K. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer. Journal of Clinical Oncology 43(18):2044-2048, 2025. e-Pub 2025. PMID: 40367400.
      4. Mohamad, O, Kouzi, ZE, Kouzy, R, Choi, S, Mok, H, Hoffman, K, Nguyen, Q, Hassanzadeh, CJ, Tang, C, Park, RJ, Shah, SJ, McGuire, SE, Mayo, LL, Kim, Y, Prajapati, S, Vijayan, S, Kudchadker, RJ, Bruno, TL, Frank, SJ. Safety and early outcomes of proton therapy and low-dose rate brachytherapy boost for patients with prostate cancer. Brachytherapy 24(2):1-9, 2025. e-Pub 2025. PMID: 40024668.
      5. Hassanzadeh, CJ, Mohamad, O, Bruno, TL, Wang, L, Kudchakar, R, Bathala, TK, Sanders, JW, Mok, H, McGuire, SE, Kuban, DA, Hoffman, K, Nguyen, Q, Park, RJ, Thames, HD, Corn, P, Chapin, BF, Choi, S, Tang, C, Frank, SJ. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
      6. Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
      7. Sosa, A, Rooney, MK, Thames, HD, Sanders, JW, Swanson, DM, Choi, S, Nguyen, Q, Mok, H, Kuban, DA, Ron Zhu, X, Shah, SJ, Mayo, LL, Hoffman, K, Tang, C, McGuire, SE, Sahoo, N, Zhang, X, Lee, AK, Pugh, T, Mahmood, U, Davis, JW, Chapin, BF, Corn, P, Kudchadker, R, Ausat, N, Frank, SJ. Proton therapy toxicity outcomes for localized prostate cancer. Clinical and Translational Radiation Oncology 48, 2024. e-Pub 2024. PMID: 39188999.
      8. Nikitas J, Ong WL, Carrier N, Romero T, Millar J, Steinberg ML, Rettig MB, Boutros PC, Reiter R, Nickols NG, Valle L, SE M, Spratt DE, Souhami L, Roy S, Martin JM, Joseph D, Nabid A, Kishan AU. Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys 119(3):826-831, 2024. e-Pub 2023. PMID: 38151191.
      9. Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, SE M, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int 132(3):307-313, 2023. e-Pub 2023. PMID: 37057728.
      10. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
      11. Zamarbide Losada JN, Sulpice E, Combe S, Almeida GS, Leach DA, Choo J, Protopapa L, Hamilton MP, McGuire S, Gidrol X, Bevan CL, Fletcher CE. Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-resistant breast cancer. J Endocrinol 256(3), 2023. e-Pub 2023. PMID: 36622663.
      12. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N. Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 39(40):6265-6285, 2020. e-Pub 2020. PMID: 31383940.
      13. Boyce-Fappiano D, Bathala TK, Ye R, Pasalic D, Gjyshi O, Pezzi TA, Noticewala SS, McGinnis GJ, Maroongroge S, Kuban DA, Nguyen QN, McGuire SE, Hoffman KE, Choi S, Tang C, Kudchadker RJ, Frank SJ. Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy. Brachytherapy 19(5):574-583, 2020. e-Pub 2020. PMID: 32682778.
      14. Abu-Gheida I, Bathala TK, Maldonado JA, Khan M, Anscher MS, Frank SJ, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Kim M, Kuban DA, Aparicio A, Chapin BF, Tang C. Increased frequency of Mesorectal and Perirectal LN involvement in T4 Prostate Cancers. Int J Radiat Oncol Biol Phys 107(5):982-985, 2020. e-Pub 2020. PMID: 32353391.
      15. Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Netw Open 3(3):e201255, 2020. e-Pub 2020. PMID: 32191331.
      16. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2020. PMID: 31742674.
      17. Pasalic D, Kuban DA, Allen PK, Tang C, Mesko SM, Grant SR, Augustyn AA, Frank SJ, Choi S, Hoffman KE, Nguyen QN, McGuire SE, Pollack A, Anscher MS. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. Int J Radiat Oncol Biol Phys 104(4):790-797, 2019. e-Pub 2019. PMID: 30836166.
      18. Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene 38(28):5700-5724, 2019. e-Pub 2019. PMID: 31043708.
      19. Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SE. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab 1(1):70-85, 2019. e-Pub 2019. PMID: 31198906.
      20. Lin C, Salzillo TC, Bader DA, Wilkenfeld SR, Awad D, Pulliam TL, Dutta P, Pudakalakatti S, Titus M, McGuire SE, Bhattacharya PK, Frigo DE. Prostate Cancer Energetics and Biosynthesis. Adv Exp Med Biol 1210:185-237, 2019. e-Pub 2019. PMID: 31900911.
      21. Koh EH, Chernis N, Saha PK, Xiao L, Bader DA, Zhu B, Rajapakshe K, Hamilton MP, Liu X, Perera D, Chen X, York B, Trauner M, Coarfa C, Bajaj M, Moore DD, Deng T, McGuire SE, Hartig SM. miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. Diabetes 67(12):2541-2553, 2018. e-Pub 2018. PMID: 30002134.
      22. Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol 36(29):2943-2949, 2018. e-Pub 2018. PMID: 30106637.
      23. Kuhn JJ, Lavender VH, Hunter LL, McGuire SE, Meinzen-Derr J, Keith RW, Greinwald JH. Ocular Vestibular Evoked Myogenic Potentials: Normative Findings in Children. J Am Acad Audiol 29(5):443-450, 2018. e-Pub 2018. PMID: 29708493.
      24. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int 121(4):540-548, 2018. e-Pub 2018. PMID: 28941030.
      25. Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire SE, Hoffman KE, Chen HC, Wang X, Swanson DA. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. Int J Radiat Oncol Biol Phys 100(2):374-382, 2018. e-Pub 2018. PMID: 29229325.
      26. Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA. Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial. Am J Clin Oncol 41(6):558-567, 2018. e-Pub 2018. PMID: 27635624.
      27. Holliday EB, Kuban DA, Levy LB, Bolukbasi Y, Master P, Choi S, Nguyen Q, McGuire SE, Mahmood U, Frank SJ, Hoffman KE. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis 4(4):384-394, 2017. e-Pub 2017. PMID: 28462945.
      28. Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, , Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE. Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Adv Radiat Oncol 2(3):249-258, 2017. e-Pub 2017. PMID: 29114589.
      29. Koh EH, Chen Y, Bader DA, Hamilton MP, He B, York B, Kajimura S, McGuire SE, Hartig SM. Mitochondrial activity in human white adipocytes is regulated by the Ubiquitin Carrier Protein 9/microRNA-30a axis. J Biol Chem 291(47):24747-24755, 2016. e-Pub 2016. PMID: 27758866.
      30. Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, Lund AH, Vang S, Stribolt K, Madsen MR, Laurberg S, McGuire SE, Ørntoft TF, Andersen CL. SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism. Mol Oncol 10(8):1266-1282, 2016. e-Pub 2016. PMID: 27396952.
      31. Holliday, EB, Kuban, DA, Bolukbasi, Y, Levy, LB, Master, P, Choi, S, Frank, SJ, McGuire, SE, Mahmood, U, Pugh, T, Hoffman, K. Outcomes after adjuvant radiation therapy for prostate cancer at a comprehensive cancer center. Journal of Radiation Oncology 5(3):287-292, 2016. e-Pub 2016.
      32. Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer. Am J Clin Oncol 39(4):368-373, 2016. e-Pub 2016. PMID: 24732810.
      33. Hamilton MP, Rajapakshe KI, Bader DA, Cerne JZ, Smith EA, Coarfa C, Hartig SM, McGuire SE. The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia 18(6):356-70, 2016. e-Pub 2016. PMID: 27292025.
      34. Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612, 2016. e-Pub 2016. PMID: 27194471.
      35. Hartig SM, Bader DA, Abadie KV, Motamed M, Hamilton MP, Long W, York B, Mueller M, Wagner M, Trauner M, Chan L, Bajaj M, Moore DD, Mancini MA, McGuire SE. Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. Mol Endocrinol 29(9):1320-33, 2015. e-Pub 2015. PMID: 26192107.
      36. Chaluvally-Raghavan P, Zhang F, Pradeep S, Hamilton MP, Zhao X, Rupaimoole R, Moss T, Lu Y, Yu S, Pecot CV, Aure MR, Peuget S, Rodriguez-Aguayo C, Han HD, Zhang D, Venkatanarayan A, Krohn M, Kristensen VN, Gagea M, Ram P, Liu W, Lopez-Berestein G, Lorenzi PL, Børresen-Dale AL, Chin K, Gray J, Dusetti NJ, McGuire SE, Flores ER, Sood AK, Mills GB. Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers. Cancer Cell 26(6):863-879, 2014. e-Pub 2014. PMID: 25490449.
      37. Wang J, Kudchadker R, Choi S, Pettaway CA, Choi H, Hobbs BD, Occena MC, McGuire SE, Pugh TJ, Hoffman K, Mahmood U, Kuban DA. Local recurrence map to guide target volume delineation after radical prostatectomy. Pract Radiat Oncol 4(6):e239-46, 2014. e-Pub 2014. PMID: 25407875.
      38. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, [Akbani R, Aldape KD, Baggerly KA, Broom BM, Chin L, Edgerton ME, Hamilton SR, Liang H, Liu Y, Lu Y, McGuire SE, Su X, Verhaak R, Wang W, Wu CJ, Yung WK, Zhang N, Research Network* ZWCGA, Benz CC, Perou CM, Stuart JM. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Collaborator on behalf of the Cancer Genome Atlas Pan-Cancer Analysis Project. Cell 158(4):929-944, 2014. e-Pub 2014. PMID: 25109877.
      39. Cerne JZ, Hartig SM, Hamilton MP, Chew SA, Mitsiades N, Poulaki V, McGuire SE. Protein Kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation. Invest Ophthalmol Vis Sci 55(4):2130-2139, 2014. e-Pub 2014. PMID: 24595385.
      40. Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074-84, 2014. e-Pub 2014. PMID: 24661661.
      41. Coarfa C, Pichot C, Jackson A, Tandon A, Amin V, Raghuraman S, Paithankar S, Lee AV, McGuire SE, Milosavljevic A. Analysis of interactions between the epigenome and structural mutability of the genome using genboree workbench tools. BMC Bioinformatics 15(7):1471-2105, 2014. e-Pub 2014. PMID: 25080362.
      42. Bader DA, Cerne JZ, McGuire SE. Recent Developments in Androgen Deprivation Therapy for Locally Advanced Prostate Cancer. Oncology & Hematology Review 10(2):133-8, 2014. e-Pub 2014.
      43. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis 16(4):346-351, 2013. e-Pub 2013. PMID: 23939133.
      44. Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 87(5):946-953, 2013. e-Pub 2013. PMID: 24139077.
      45. Weinstein JN, Collison EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM, [Akbani R, Aldape KD, Baggerly KA, Broom BM, Chin L, Edgerton ME, Hamilton SR, Liang H, Liu Y, Lu Y, McGuire SE, Su X, Verhaak R, Wang W, Wu CJ, Yung WK, Zhang N, Zhang W. Cancer Genome Atlas Research Network*. The Cancer Genome Atlas Pan-Cancer analysis project. *Collaborator on behalf of the Cancer Genome Atlas Pan-Cancer Analysis Project. Nature Genetics 45(10):1113-1120, 2013. e-Pub 2013. PMID: 24071849.
      46. Nguyen QN, Levy LB, Lee AK, Choi S, Frank SJ, Pugh TJ, McGuire SE, Hoffman KE, Kuban DA. Long-term Outcomes For Men With High-Risk Prostate Cancer Treated Definitively With External Beam Radiotherapy With and Without Androgen Deprivation. Cancer 119(18):3265-3271, 2013. e-Pub 2013. PMID: 23798338.
      47. Hartig SM, Feng Q, Ochsner SA, Xiao R, McKenna NJ, McGuire SE, He B. Androgen receptor agonism promotes an osteogenic gene program in preadipocytes. Biochem Biophys Res Commun 434(2):357-362, 2013. e-Pub 2013. PMID: 23567971.
      48. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Radiat Oncol Biol Phys 85(3):693-699, 2013. e-Pub 2013. PMID: 22836052.
      49. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-209, 2013. e-Pub 2013. PMID: 22673704.
      50. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim 38(3):251-254, 2013. e-Pub 2013. PMID: 23540491.
      51. Hamilton MP, Rajapakshe K, Hartig SM, Reva B, McLellan MD, Kandoth C, Ding L, Zack TI, Gunaratne PH, Wheeler DA, Coarfa C, McGuire SE. Identification of a pan-cancer oncogenic microRNA superfamily anchored by a central core seed motif. Nat Commun 4(4):2730, 2013. e-Pub 2013. PMID: 24220575.
      52. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 2013. e-Pub 2013. PMID: 23102837.
      53. Hartig SM, He B, Newberg JY, Ochsner SA, Loose DS, Lanz RB, McKenna NJ, Buehrer BM, McGuire SE, Marcelli M, Mancini MA. Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol 19(9):1126-1141, 2012. e-Pub 2012. PMID: 22999881.
      54. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation theray to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-2352, 2012. e-Pub 2012. PMID: 22357249.
      55. Cerne JZ, Zong L, Jelinek J, Hilsenbeck SG, Wang T, Oesterreich S, McGuire SE. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients. Breast Cancer Res Treat 135(1):135-143, 2012. e-Pub 2012. PMID: 22706629.
      56. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Pract Radiat Oncol 2(3):e7-e13, 2012. e-Pub 2012. PMID: 24674130.
      57. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease?. Eur J Cancer 48(11):1664-1671, 2012. e-Pub 2012. PMID: 22336663.
      58. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, 2012. e-Pub 2012. PMID: 22290249.
      59. Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich S. A SNP in steroid receptor co-activator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol 26(2):220-227, 2012. e-Pub 2012. PMID: 22174377.
      60. Hartmaier RJ, Tchatchou S, Richter AS, Wang J, McGuire SE, Skaar TC, Rae JM, Hemminki K, Sutter C, Ditsch N, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Wappenschmidt B, Schmutzler RK, Meindl A, Bartram CR, Burwinkel B, Oesterreich S. Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. BMC Cancer 9(9):438, 2009. e-Pub 2009. PMID: 20003447.
      61. McGuire SE, McGuire AL. Don't throw the baby out with the bathwater: enabling a bottom-up approach in genome-wide association studies. Genome Res 18(11):1683-5, 2008. e-Pub 2008. PMID: 18974262.
      62. McGuire SE, Frank SJ, Eifel PJ. Treatment of recurrent vaginal melanoma with external beam radiation therapy and palladium-103 brachytherapy. Brachytherapy 7(4):359-363, 2008. e-Pub 2008. PMID: 18778972.
      63. Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, Cox JD, Hui Z, Li Y, Newhauser WD, Mohan R, Liao Z. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72(1):278-287, 2008. e-Pub 2008. PMID: 18722278.
      64. Dawood S, Broglio K, Kau SW, Islam R, Symmans WF, Buchholz TA, McGuire SE, Meric-Bernstam F, Cristofanilli M, Hortobágyi GN, Gonzalez-Angulo AM. Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist 13(1):6-15, 2008. e-Pub 2008. PMID: 18245008.
      65. McGuire AL, Cho MK, McGuire SE, Caulfield T. The future of personal genomics. Science 317(5845)(1687):1687, 2007. e-Pub 2007. PMID: 17885116.
      66. McGuire SE, Gonzalez-Angulo AM, Huang EH, Tucker SL, Kau SW, Yu TK, Strom EA, Oh JL, Woodward WA, Tereffe W, Hunt KK, Kuerer HM, Sahin AA, Hortobagyi GN, Buchholz TA. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 68(4):1004-1009, 2007. e-Pub 2007. PMID: 17418973.
      67. Alkhatib AA, McGuire SE. Photo Quiz. Sine waves. Neth J Med 65(4):153, 155, 2007. e-Pub 2007. PMID: 17452766.
      68. McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in Drosophila. Sci STKE 2004(220):pl6, 2004. e-Pub 2004. PMID: 14970377.
      69. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of memory dysfunction in Drosophila. Science 302(5651):1765-1768, 2003. e-Pub 2003. PMID: 14657498.
      70. McGuire SE, Le PT, Davis RL. The role of Drosophila mushroom body signaling in olfactory memory. Science 293(5533):1330-1333, 2001. e-Pub 2001. PMID: 11397912.
      71. Lee AV, Weng CN, McGuire SE, Wolf DM, Yee D. Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor. Biotechniques 23(6):1062-1068, 1997. e-Pub 1997. PMID: 9421637.
      72. Yee D, McGuire SE Brünner N, Kozelsky TW, Allred DC, Chen SH, Woo SL. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7(10):1251-1257, 1996. e-Pub 1996. PMID: 8793549.
      73. Lehming N, McGuire SE, Brickman JM, Ptashne M. Interactions of a Rel protein with its inhibitor. Proc Natl Acad Sci U S A 92(22):10242-10246, 1995. e-Pub 1995. PMID: 7479760.
      74. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 77(1):25-32, 1994. e-Pub 1994. PMID: 7512885.
      75. McGuire SE, Fuqua SA, Naylor SL, Helin-Davis DA, McGuire WL. Chromosomal assignments of human 27-kDa heat shock protein gene family. Somat Cell Mol Genet 15(2):167-71, 1989. e-Pub 1989. PMID: 2538929.

      Invited Articles

      1. McGuire SE, Buchholz TA. Postsurgical radiation therapy in patients with complete response to neoadjuvant chemotherapy. Current Breast Cancer Reports 1(86-89):1946-4588, 2009. e-Pub 2009.

      Review Articles

      1. Bader DA, McGuire SE. Tumour metabolism and its unique properties in prostate adenocarcinoma. Nat Rev Urol 17(4):214-231, 2020. e-Pub 2020. PMID: 32112053.
      2. Hartig SM, Hamilton MP, Bader DA, McGuire SE. The miRNA Interactome in Metabolic Homeostasis. Trends Endocrinol Metab 26(12):733-45, 2015. e-Pub 2015. PMID: 26492831.
      3. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 95(4):433-437, 2008. e-Pub 2008. PMID: 18161887.
      4. Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23(28):7098-7104, 2005. e-Pub 2005. PMID: 16192593.
      5. McGuire SE, Deshazer M, Davis RL. Thirty years of olfactory learning and memory research in drosophila melanogaster. Prog Neurobiol 76(5):328-347, 2005. e-Pub 2005. PMID: 16266778.
      6. McGuire SE, Roman G, Davis RL. Gene expression systems in drosophila: a synthesis of time and space. Trends Genet 20(8):384-391, 2004. e-Pub 2004. PMID: 15262411.
      7. McGuire SE, Davis RL. Presenilin-1 and memories of the forebrain. Neuron 32(5):763-765, 2001. e-Pub 2001. PMID: 11738022.

      Other Articles

      1. McGuire SE Deciphering Genomic Risk in Prostate Cancer-Ready for Prime Time. JAMA Oncol 7(4):553-554, 2021. PMID: 33570544.
      2. Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N Correction: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 39(40):6387-6392, 2020. PMID: 32820250.
      3. McGuire SE DNA Damage and Repair Pathway Profiles as Biomarkers in High-Risk Prostate Cancer. JAMA Oncol 2(4):480-481, 2016. PMID: 26747678.
      4. McGuire, SE, Deshazer, M, Davis, RL Corrigendum to "Thirty years of olfactory learning and memory research in Drosophila melanogaster" [Progress in Neurobiology 76 (2005) 328-347] (DOI:10.1016/j.pneurobio.2005.09.003). Prog. Neurobiol 79(5-6):341-342, 2006.

      Editorials

      1. Chapin BF, McGuire SE, Aparicio A. Is treatment of the primary tumor in metastatic prostate cancer justified?. Eur Urol 65(6):1067-1068, 2014. PMID: 24411278.

      Abstracts

      1. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen GN, Frank SJ, Pugh T, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Rad Oncol Biol Phys 81(2):S 40 - S 41, 2011. e-Pub 2011.
      2. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Choi S, Nguyen Q, Hoffman K, Swanson SE. Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI. Int J Rad Oncol Biol Phys 81(2):S 398, 2011. e-Pub 2011.
      3. Kim MM, Hoffman KE, Levy LB, Frank SJ, Choi S, Nguyen QN, Pugh TJ, McGuire SE, Lee AK, Kuban DA. Prostate Cancer-Specific Mortality After Definitive Radiation Therapy: Who Dies of Disease?. Proceedings of the 2011 Genitourinary Cancers Symposium, 2011. e-Pub 2011.
      4. Kim MM, Hoffman KE, Levy LB, Master P, Frank SJ, Choi S, Nguyen QN, McGuire SE Lee AK, Kuban DA. Improvement in Prostate Cancer Outcomes Over Time: A Twenty-Year Analysis. Int J Rad Oncol Phys 78(3):S 191 (#1115), 2010. e-Pub 2010. PMID: 23798338.
      5. McGuire SE, Levy LB, Settle SH, Choi S, Nguyen QN, Hoffman KE, Frank SJ, Lee AK, Kuban DA. PSA Response to Neoadjuvant Androgen Suppression Therapy Prior to High Dose Radiotherapy Predicts Survival in Clinically Localized High Risk Prostate Cancer. Int J Rad Oncol Phys 78(3):S 124 (#265), 2010. e-Pub 2010.
      6. Ludwig MS, Lee AK, McGuire SE, Choi S, Nguyen QN, Frank SJ, Kuban DA. Influence of Prognostic Factors on Duration of Hormone Therapy and Outcomes. Proceedings of the 92nd Annual Meeting of The American Radium Society, 2010. e-Pub 2010.
      7. Kuban DA, Noueras-Gonzalez GM, Hamblin L, Lee AK, Coi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation. Int J Rad Oncol Phys 78(3):S58 (#124), 2010. e-Pub 2010.
      Read More
      Less

      Patient Reviews


      CV information above last modified August 20, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top